Drug intelligence / Profile preview

KIN-302

Development stage: Preclinical
Lead developer: Kinimmune
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Parenteral

Overview

KIN-302 is an undisclosed, systemically administered cytokine-based immunotherapeutic candidate under development by Kinimmune. Part of the company's KIN-300 series, KIN-302 is designed to achieve localized immune stimulation within tumor tissues following systemic delivery, thereby expanding the therapeutic window of cytokine therapy while mitigating systemic toxicities. The program is currently in the discovery stage of preclinical development for the treatment of solid tumors.

Beyond the preview

Go deeper on KIN-302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIN-302.

Explore the full profile